Pear Therapeutics (NASDAQ:PEAR – Get Rating) and Sharecare (NASDAQ:SHCR – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
This table compares Pear Therapeutics and Sharecare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Pear Therapeutics and Sharecare’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pear Therapeutics||$4.21 million||55.71||-$65.14 million||N/A||N/A|
|Sharecare||$412.82 million||1.43||-$85.00 million||($0.30)||-5.57|
Volatility & Risk
Pear Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Sharecare has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Pear Therapeutics and Sharecare, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pear Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 402.96%. Sharecare has a consensus price target of $5.13, suggesting a potential upside of 206.89%. Given Pear Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Pear Therapeutics is more favorable than Sharecare.
Insider and Institutional Ownership
55.4% of Pear Therapeutics shares are owned by institutional investors. Comparatively, 25.4% of Sharecare shares are owned by institutional investors. 30.7% of Pear Therapeutics shares are owned by insiders. Comparatively, 30.4% of Sharecare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Pear Therapeutics beats Sharecare on 9 of the 12 factors compared between the two stocks.
About Pear Therapeutics
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Sharecare, Inc. operates as a digital healthcare platform company. Its Sharecare platform connects people, patients, providers, employers, health plans, government organizations, and communities that optimize individual and population-wide well-being. The company offers enterprise solutions based on a software-as-a-service model that allows enterprise clients to message, motivate, and manage their populations, as well as measure their population progress; a suite of data and information-driven solutions; and life sciences solutions, which provides members with personalized information, programs, and resources to enhance their health and well-being. It also operates RealAge, a platform for health assessment to assess behaviors and existing conditions of its members and provide metric for their physical health. In addition, the company provides secure, automated release of information, audit, and business consulting services to streamline the medical records process for medical facilities. It sells its solutions through direct sales organization and partner relationships. Sharecare, Inc. was founded in 2009 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.